Healthcare

Growth in the telehealth and telemedicine market is mainly driven by factors such as the rising population, the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, government support, increasing awareness. The  teledermatology market  accounted for US$ 4.5 billion in 2019 and is estimated to be US$ 44.8 billion by 2029 and is anticipated to register a CAGR of 26.0%. The report " Global Teledermatology Market, By Type (Telehospitals, Telehomes, and MHealth (Mobile Health) ,  and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In May 2020, DermTech, announced the launch of its DermTech pigmented Lesion Assay, a telemedicine solution to enable remote use of its non-invasive adhesive patch test for melanoma detection. In April 2020, Sakhiya Skin Clinic in India announced the

Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast period. The introduction of new products based on scientific mechanistic understanding such as the identification of new T-cell subsets, particularly Th17, and Th22 and the patent expiration of PROTOPIC (tacrolimus) is expected to open up new avenues for manufacturers to capitalize on over the forecast period. The  pruritus therapeutics market  accounted for US$ 3.85 billion in 2019 and is anticipated to register a CAGR of 12.5%. The report " Global Pruritus Therapeutics Market, By Disease Type (Internal Diseases, Atopic Dermatitis, Allergic, and Others), By Treatment ( Corticosteroids, and Antihistamines ),   and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In March 2019, Regeneron Pharmaceuticals and Sanofi received the U

  Immunodiagnostics  is a field of in vitro diagnostics that uses antigen antibody responses to diagnose disease. It is used to diagnose infectious infections as well as chronic diseases such as cancer and autoimmune disorders. It is used to treat cardiovascular diseases, infectious diseases, autoimmune disorders, endocrinology, and oncology, among other things. The human immune system is a complicated network of interconnected cells. Immunodiagnostics have advanced significantly, allowing for more accurate diagnosis of this complicated interacting network. The rise in the frequency and prevalence of infectious disorders (HIV, hepatitis, and other sexually transmitted infections), cardiovascular diseases, malignancies, and other chronic diseases has bolstered the immunodiagnostics industry. Furthermore, the expanding senior population, as well as changing lifestyle and demography, drive the market. The worldwide immunodiagnostics market is being driven by technological advancement and

  The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. Currently, about 10% of all diabetes cases are Type-1 and the remaining are of Type-2. The  diabetes drugs market  accounted for US$ 51.4 billion in 2019 and is estimated to be US$ 93.6 billion by 2029 and is anticipated to register a CAGR of 6.20%. The report " Global Diabetes Drugs Market,  By Diabetes Type ( Type 1 and Type 2 ), By Drug Class ( Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others ), By Distribution Channel (Online pharmacies, Hospital Pharmacies, and Retail Pharmacies),  and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In April 2019, Glenmark Pharmaceuticals announced that it plans to bring its Remogliflozi